# A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers

> **NCT02514603** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 12 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** Prexasertib

## Key facts

- **NCT ID:** NCT02514603
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2017-04-10
- **Final completion:** 2017-04-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02514603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02514603, "A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02514603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*